A detailed statistical analysis of individual ApoC1 values, histological diagnoses, treatment course, and survival time will be mandatory to answer the question of whether ApoC1 serum levels qualify as a biomarker for glioblastoma. This evidence concerns the gene APOC1 and glioblastoma.